Immunize
Respiratory Syncytial Virus Vaccine
search
Respiratory Syncytial Virus Vaccine
, RSV Vaccine, Palivizumab, Synagis
Mechanism
Humanized mouse
Monoclonal Antibody
to RSV
Indications
Based on AAP guidelines
Chronic lung disease in age <2 years
Medication treatment within 6 months of RSV season start
Hemodynamically significant
Congenital Heart Disease
in age <2 years
Consider in infants with severe
Immunodeficiency
Preterm Infant
s during their first RSV season
Gestational age
at birth <28 weeks (Give during first RSV season)
Gestational age
at birth 28-32 weeks who are under age 6 months during RSV season
Gestational age
32-35 weeks with 2 risk factors:
Day care attendance
Siblings under 5 years of age
Congenital airway abnormality
Congenital neuromuscular disease
Dosing
Palivizumab 1 dose IM monthly for 5 months of RSV season (November 1 to March 1)
Efficacy
Decreases hospitalizations by 45 to 55%
References
Pickering (2009) Red Book, AAP, Elk Grove Village, p. 560
Type your search phrase here